Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jan-Feb;25(1):64-67.
doi: 10.1016/j.rpor.2019.12.010. Epub 2019 Dec 16.

Single dose radiotherapy in soft tissue tumoral masses: just enough palliation

Andrés Vargas  1
Affiliations
Case Reports

Single dose radiotherapy in soft tissue tumoral masses: just enough palliation

Andrés Vargas. Rep Pract Oncol Radiother. 2020 Jan-Feb.

Abstract

Introduction: Single fraction radiotherapy (SFR) is effective in palliation of symptoms related to advanced cancer. Despite this, several studies have shown that the trend towards multiple fraction treatment (MFR) is largely maintained. Even in patients with limited life expectancy, SFR is significantly underutilized in current practice.

Cases description: Four patients diagnosed with advanced cancer who developed soft tissue lesions were treated with SFR due to frailty and/or a poor performance status.

Conclusion: Despite the effectiveness of SFR is well-established in BM, its use in symptoms caused by soft tissue lesions have been underreported. SFR could be a good option for providing palliation in some patients, particularly in those who are frail or have a poor performance status.

Keywords: Multifraction radiotherapy; Palliative radiotherapy; Single fraction radiotherapy; Soft tissue metastases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Case study 1. (a) Pretreatment right shoulder mass. Isodose lines: yellow (100%) and blue (90%). (b) Clinical response 6 weeks postradiation treatment.
Fig. 2
Fig. 2
Case study 2. (a) Pretreatment left hiliar mass. Isodose lines: yellow (100%) and blue (90%). (b) Clinical response 6 weeks postradiation treatment.
Fig. 3
Fig. 3
Case study 3. (a) Pretreatment anal and groins masses. Isodose lines: yellow (100%) and blue (90%) (b) Clinical response 6 weeks postradiation treatment.
Fig. 4
Fig. 4
Case study 4. (a) Pretreatment anal mass. Isodose lines: yellow (100%) and blue (90%). (b) Clinical response 8 weeks post 10 Gy SFR. (c) Clinical response 6 weeks post 30 Gy/10 fractions.
See this image and copyright information in PMC

References

    1. Cameron M.G., Kersten C., Vistad I., Fossa S., Guren M.G. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review. Acta Oncologica. 2014;53:164–173. - PMC - PubMed
    1. Stevens R., Macbeth F., Toy E., Coles B., Lester J.F. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015 Issue 1. Art. No.: CD002143. - PMC - PubMed
    1. Fairchild A., Harris K., Barnes E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26:4001–4011. - PubMed
    1. Steenland E., Leer J.W., van Houwelingen H. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52(2):101. - PubMed
    1. Hartsell W.F., Scott C.B., Bruner D.W. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798. - PubMed

Publication types